Global Blood Therapeutics announces employment inducement grants » 08:0905/0705/07/21
Global Blood Therapeutics…
Global Blood Therapeutics announced that on May 1, 2021, the compensation committee of GBT's board of directors granted 14 new employees restricted stock units for an aggregate of 26,450 shares of the company's common stock. These awards were made under GBT's Amended and Restated 2017 Inducement Equity Plan. The above-described awards were each granted as an inducement material to the employees entering into employment with the company in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The Plan was adopted by GBT's board of directors in January 2017 and has been amended and restated from time to time.
Global Blood Therapeutics price target lowered to $110 from $120 at Cantor Fitzgerald » 07:0905/0705/07/21
Cantor Fitzgerald analyst…
Cantor Fitzgerald analyst Alethia Young lowered the firm's price target on Global Blood Therapeutics to $110 from $120 and keeps an Overweight rating on the shares, citing higher expenses. Young thinks that the stock may begin to recover before the new script acceleration is realized, and views current levels baking in limited growth potential for Oxbryta.
|Over a week ago|
Global Blood price target lowered to $45 from $50 at Piper Sandler » 04:5505/0605/06/21
Piper Sandler analyst…
Piper Sandler analyst Joseph Catanzaro lowered the firm's price target on Global Blood Therapeutics to $45 from $50 and keeps a Neutral rating on the shares. The company reported Q1 Oxbryta revenue of $39M, a sequential decline that was "perhaps not unexpected" given prior guidance, Catanzaro tells investors in a research note. The analyst believes fiscal 2021 numbers likely need to come down further once again since the challenging commercial dynamics "could persist for Oxbryta in perpetuity."
Global Blood Therapeutics reports Q1 EPS ($1.21), consensus ($1.01) » 16:2105/0505/05/21
Reports Q1 revenue…
Reports Q1 revenue $39.04M, consensus $43M.
Fly Intel: Top five analyst initiations » 09:5704/1404/14/21
HOG, HTH, PERI, GBT, DEN
Catch up on today's…
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Harley-Davidson (HOG) initiated with a Buy at BofA. 2. Hilltop Holdings (HTH) initiated with a Neutral at Piper Sandler. 3. Perion Network (PERI) initiated with a Hold at Stifel. 4. Global Blood Therapeutics (GBT) initiated with an Outperform at SVB Leerink. 5. Denbury (DEN) initiated with an Overweight at KeyBanc. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
SVB Leerink bullish on Global Blood Therapeutics, initiates with an Outperform » 08:5104/1404/14/21
As previously reported,…
As previously reported, SVB Leerink analyst Andrew Berens initiated coverage of Global Blood Therapeutics with an Outperform rating and $54 price target. The analyst sees two primary ways for investors to win, namely Oxbryta sales beginning to accelerate after the pandemic environment alleviates, and/or the untapped value within the company's multi-faceted SCD-focused pipeline becoming incrementally realized. Overall, Berens believes the main reason to own Global Blood longer-term is for the pipeline.
Global Blood Therapeutics initiated with an Outperform at SVB Leerink » 06:1704/1404/14/21
SVB Leerink analyst…
SVB Leerink analyst Andrew Berens initiated coverage of Global Blood Therapeutics with an Outperform rating and $54 price target.
|Over a month ago|
Global Blood Therapeutics announces 72-week data from HOPE study published » 05:1004/0804/08/21
Global Blood Therapeutics…
Global Blood Therapeutics announced The Lancet Haematology has published the complete analysis of 72-week data from the Phase 3 HOPE Study of Oxbryta( tablets in patients with sickle cell disease, or SCD. The results showed significant and sustained improvement in hemoglobin levels, reduction in hemolysis and improved overall health status in patients treated with Oxbryta. These findings support the long-term use of Oxbryta to reduce hemolytic anemia and hemolysis in SCD, potentially mitigating life-threatening complications of the condition. Oxbryta, a first-in-class oral, once-daily therapy, directly inhibits hemoglobin polymerization, the root cause of the sickling and destruction of red blood cells in SCD. Oxbryta is approved in the United States for the treatment of SCD in patients ages 12 years and older. The HOPE Study, a randomized, double-blind, placebo-controlled, international, multicenter trial in 274 patients ages 12 to 65 years with SCD, showed treatment with the U.S. FDA-approved dose of Oxbryta 1500 mg resulted in rapid and durable improvements in hemoglobin levels throughout 72 weeks of treatment. Approximately 90% of patients treated with Oxbryta achieved a hemoglobin improvement of greater than1 g/dL from baseline at one or more time points during the study compared to placebo. In addition, approximately 59% of patients treated with Oxbryta 1500 mg were able to achieve a hemoglobin increase of greater than2 g/dL and 20 percent achieved greater than 3 g/dL at one or more time points, compared to approximately 3% and no patients in the placebo group, respectively. The analysis also showed that study participants treated with Oxbryta had numerically fewer vaso-occlusive crises, or VOCs, consistent with the trends at 24 weeks, and were three times less likely to experience an acute anemic episode. Additionally, approximately 74% of patients taking Oxbryta had their overall clinical status rated as "moderately improved" or "very much improved" by their clinician compared with approximately 47% of the placebo group, a statistically significant difference. Treatment with Oxbryta remained generally well tolerated, and rates of adverse events were similar between treatment groups over 72 weeks. Findings from a post hoc analysis of the HOPE Study published recently in the American Journal of Hematology evaluated the incidence and outcomes of leg ulcers in SCD patients and further support the foundational role of hemoglobin S polymerization inhibition in SCD treatment. Results of the analysis showed leg ulcers improved or resolved by week 72 in all patients receiving Oxbryta 1500 mg compared with 63% of patients in the placebo group. Resolution of leg ulcers was associated with increases in hemoglobin levels and decreases in hemolysis. Patients who experienced a hemoglobin increase of greater than 1.0 g/dL while treated with Oxbryta were most likely to experience resolution of their leg ulcers within 24 weeks. These results highlight the potential of Oxbryta to meaningfully impact major patient outcomes.
Global Blood Therapeutics announces employment inducement grants » 08:2204/0504/05/21
Global Blood Therapeutics…
Global Blood Therapeutics announced that on April 1, 2021, the compensation committee of GBT's board of directors granted 12 new employees restricted stock units for an aggregate of 47,750 shares of the company's common stock. These awards were made under GBT's Amended and Restated 2017 Inducement Equity Plan. The above-described awards were each granted as an inducement material to the employees entering into employment with the company in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The Plan was adopted by GBT's board of directors in January 2017 and has been amended and restated from time to time.
Global Blood Therapeutics appoints Alexis Thompson to board of directors » 07:1303/1803/18/21
Global Blood Therapeutics…
Global Blood Therapeutics announced the appointment of AlexisThompson to the company's board of directors. Dr. Thompson will serve on the board's research and development committee. A board-certified pediatric hematologist, Dr. Thompson is head of the Hematology Section and director of the Comprehensive Thalassemia Program at the Ann and Robert H. Lurie Children's Hospital of Chicago, where she also serves as the A. Watson and Sarah Armour Endowed Chair for Childhood Cancer and Blood Disorders. In addition, Dr. Thompson is associate director for equity and minority health at the Robert H. Lurie Cancer Center and Northwestern University Feinberg School of Medicine.